Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Net Cash Flow (2016 - 2025)

Organogenesis Holdings has reported Net Cash Flow over the past 10 years, most recently at $30.0 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $30.0 million for Q4 2025, down 27.33% from a year ago — trailing twelve months through Dec 2025 was -$41.8 million (down 231.46% YoY), and the annual figure for FY2025 was -$41.8 million, down 231.46%.
  • Net Cash Flow for Q4 2025 was $30.0 million at Organogenesis Holdings, up from -$9.4 million in the prior quarter.
  • Over the last five years, Net Cash Flow for ORGO hit a ceiling of $41.2 million in Q4 2024 and a floor of -$36.8 million in Q2 2025.
  • Median Net Cash Flow over the past 5 years was $612000.0 (2023), compared with a mean of $476250.0.
  • Biggest five-year swings in Net Cash Flow: soared 1116.13% in 2024 and later plummeted 3353.67% in 2025.
  • Organogenesis Holdings' Net Cash Flow stood at $11.8 million in 2021, then crashed by 140.08% to -$4.7 million in 2022, then soared by 216.53% to $5.5 million in 2023, then surged by 647.78% to $41.2 million in 2024, then fell by 27.33% to $30.0 million in 2025.
  • The last three reported values for Net Cash Flow were $30.0 million (Q4 2025), -$9.4 million (Q3 2025), and -$36.8 million (Q2 2025) per Business Quant data.